Pancreatic Cancer
CSHL has several researchers working on pancreatic cancer. David Tuveson, M.D., Ph.D., Professor, directs the Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL.
Help fund this research
Donate Now
* NOTE: On the donation form indicate in the comments field that you want your donation to go towards pancreatic cancer research.
Lustgarten Foundation Pancreatic Cancer Research Laboratory
The Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL, led by David Tuveson, M.D., Ph.D. is centered on early detection, drug development and drug delivery. The research will focus initially on three key aspects of pancreatic cancer:
- Developing ways to detect pancreatic cancer early—The presence of cancer in the pancreas causes changes in a person’s system that may be detected in bodily fluids, such as blood or urine. These changes will be identified so that they can be used to routinely test patients for the presence of pancreatic cancer in its earliest stages.
- Identifying new targets for drug development—New pathways will be explored that could potentially uncover new therapeutic approaches for drug development to kill and eliminate pancreatic cancers.
- Using more effective approaches to deliver drugs directly to pancreatic cancers—Existing research shows that pancreatic tumors are difficult to penetrate with chemotherapy, so new methods will be developed to ensure that the chemotherapy reaches the tumor for more effective treatment.
In addition to directing the Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL, Dr. Tuveson is also the Director of Research for the Lustgarten Foundation. In this capacity, he oversees the development of fundable research and works with the Foundation’s Pancreatic Cancer Research Consortium of six, world-renowned medical institutions to identify, prioritize and develop targeted research aimed at ultimately finding a cure for this deadly disease.
- Mikala Egeblad, Ph.D.
- Douglas Fearon, Ph.D.
- David Tuveson, M.D., Ph.D.
NCI grants support ‘natural’ cancer research
August 11, 2025
CSHL’s Moses lab uses a technique called click chemistry to create new, nature-based compounds that could one day be used in the clinic.
At the Lab: Catch me if you cancer
June 3, 2025
You’ve seen her on FOX and the cover of Newsday. Now, hear about the knowledge gaps that make her discovery so crucial and the noble goals driving it.
In pancreatic cancer, a race against time
April 2, 2025
By the time it’s diagnosed, it’s often too late. Now, Cold Spring Harbor Laboratory researchers have found a way to intercept the deadly disease.
Cocktails & Chromosomes: Cancer’s identity crisis
December 19, 2024
CSHL Professor Christopher Vakoc shares his research with a standing-room-only crowd at Industry bar in Huntington, NY.
Flipping cancer’s off switch
November 7, 2024
CSHL Professor Christopher Vakoc and postdoc Olaf Klingbeil have found a potential drug target for some of the most common and deadly cancers.
At the Lab Season 1 Research Rewind: Cancer
October 8, 2024
As the first season of our new podcast winds down, we’re revisiting all of our episodes with a focus on CSHL’s cutting-edge cancer research.
Old chemo drug, new pancreatic cancer therapy?
August 26, 2024
CSHL scientists have found that folinic acid makes immunotherapy therapy more effective against pancreatic ductal adenocarcinoma in mice.
How to stop cancer cachexia? Start at the top
July 8, 2024
Professor Bo Li and a team of collaborators from four CSHL labs have discovered a new potential drug target for the lethal wasting disease.
At the Lab Episode 13: A more sustainable chemistry
July 2, 2024
For this week’s podcast, CSHL Professor John Moses bridges the gap between chemistry and biology in less than three minutes.
Pancreatic cancer’s cellular amnesia
June 17, 2024
New study from CSHL Professor Christopher Vakoc and former postdoc Diogo Maia-Silva shows how basal-like cancer cells lose their original identity.